Benjamin J. Hindson - Jul 19, 2023 Form 4 Insider Report for 10x Genomics, Inc. (TXG)

Role
President and Chief Scientific Officer, Director
Signature
/s/ Eric S. Whitaker, as Attorney-in-Fact for Benjamin J. Hindson
Stock symbol
TXG
Transactions as of
Jul 19, 2023
Transactions value $
-$760,342
Form type
4
Date filed
7/21/2023, 05:31 PM
Previous filing
May 25, 2023
Next filing
Aug 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TXG Class A Common Stock Options Exercise $65.4K +13K +4.56% $5.04* 297K Jul 19, 2023 Direct
transaction TXG Class A Common Stock Options Exercise $11.1K +968 +0.33% $11.48* 298K Jul 19, 2023 Direct
transaction TXG Class A Common Stock Sale -$837K -13.9K -4.68% $60.03 284K Jul 19, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TXG Stock Option (right to buy) Options Exercise $0 -13K -100% $0.00* 0 Jul 19, 2023 Class A Common Stock 13K $5.04 Direct F3
transaction TXG Stock Option (right to buy) Options Exercise $0 -968 -3.1% $0.00 30.3K Jul 19, 2023 Class A Common Stock 968 $11.48 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 13, 2023.
F2 This transaction was executed in multiple trades at prices ranging from $60.00 to $60.16. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F3 All of the shares subject to the option are fully vested and exercisable as of the date hereof.

Remarks:

President and Chief Scientific Officer